KNSA

Business Context and Reporting Period

Kiniksa Pharmaceuticals International, Plc (KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating assets. The primary commercial product is ARCALYST (rilonacept), used for recurrent pericarditis and Cryopyrin-Associated Periodic Syndromes. The company also has a pipeline including abiprubart and mavrilimumab. This report covers the quarterly period ended September 30, 2024. Notably, the company completed a Redomiciliation from Bermuda to the United Kingdom on June 27, 2024.

Key Financial Metrics

Liquidity: As of September 30, 2024, the company held $97.4 million in cash and cash equivalents and $126.4 million in short-term investments. Management expects these resources to fund operations for at least the next 12 months.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 67% in Q3 2024 compared to Q3 2023, driven primarily by a 73% increase in ARCALYST product revenue due to increased patient enrollment.
• Expense Increases:
  • Cost of Goods Sold (COGS): Increased 121% in Q3 2024 ($20.1M vs $9.1M), attributed to higher sales volume and a $6.3 million increase in technology transfer costs for ARCALYST manufacturing.
  • Collaboration Expenses: Increased 70% in Q3 2024 ($29.3M vs $17.3M) due to the profit-sharing agreement with Regeneron tied to increased ARCALYST sales.
  • R&D Expenses: Increased 52% in Q3 2024 ($26.1M vs $17.1M), driven by the initiation of the Phase 2b clinical trial for abiprubart in Sjögren's Disease and manufacturing costs.
  • Selling, General & Administrative (SG&A): Increased 35% in Q3 2024 ($46.4M vs $34.5M), largely due to salesforce expansion and personnel costs.
• Tax Provision: The company recorded an income tax provision of $5.5 million in Q3 2024, compared to $5.4 million in Q3 2023. This is primarily due to income earned in the UK, Switzerland, and the U.S., offset by tax credits.

Guidance, Outlook, and Risks

• Outlook: Management believes current cash and investments are sufficient to fund operations for at least 12 months. The company continues to commercialize ARCALYST and advance clinical trials for abiprubart (RA and Sjögren's Disease) and mavrilimumab.
• Technology Transfer: A critical ongoing activity is the technology transfer of ARCALYST drug substance manufacturing from Regeneron to Samsung Biologics. This process involves significant risks, including potential delays, regulatory hurdles, and supply chain disruptions.
• Key Risks:
  • Manufacturing Reliance: Dependence on third-party manufacturers (Regeneron and Samsung) for ARCALYST supply.
  • Reimbursement: Potential for third-party payors to restrict coverage or demand price concessions for ARCALYST.
  • Clinical Development: Uncertainty regarding the success and timeline of clinical trials for abiprubart and mavrilimumab.
  • Capital Needs: History of losses and potential need for additional financing to sustain operations beyond the current runway.

Investor Verification Checklist

• Manufacturing Transition: Verify the status and timeline of the ARCALYST technology transfer to Samsung Biologics and any potential supply risks.
• ARCALYST Sales Trajectory: Monitor patient enrollment rates and payer coverage trends to assess the sustainability of revenue growth.
• Cash Burn Rate: Track operating cash flow and capital expenditure requirements to confirm the 12-month liquidity runway.
• Clinical Milestones: Review upcoming data readouts for abiprubart in Sjögren's Disease and RA, as well as mavrilimumab partnership opportunities.
• Regulatory Environment: Assess potential impacts of the Redomiciliation to the UK on tax liabilities and regulatory compliance.